Shattuck gears up for go/no go year
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
The company makes no secret of the need for durability with its anti-CD47 project SL-172154.
Early data on Hansoh’s HS-20089 were enough to tempt GSK, but Seagen isn't far behind.
Excluding BRCA-positive patients could be the key to Imfinzi’s apparent success in ovarian cancer, Astra’s Duo-O suggests.